There’s no excuse for this not to be commonplace in every US county and nation state.
Sequencers now cost the same as a Tesla:
With US sales halted and lawsuits underway, Qiagen’s bumpy ride into the NGS market has already begun. The competition for the smaller-scale, clinical markets is as fierce as ever. However, with automated sequencers bearing the same cost as a new car, those standing to benefit will be the biotech upstarts and clinical users just beginning to adopt their first desktop instrument.